| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 438 | 2024 | 457 | 84.430 |
Why?
|
| Kidney Failure, Chronic | 373 | 2024 | 420 | 78.670 |
Why?
|
| Renal Insufficiency, Chronic | 261 | 2024 | 293 | 71.180 |
Why?
|
| Humans | 927 | 2024 | 6794 | 34.960 |
Why?
|
| Kidney Diseases | 90 | 2024 | 121 | 26.640 |
Why?
|
| Kidney | 131 | 2024 | 184 | 26.350 |
Why?
|
| Kidney Transplantation | 65 | 2024 | 101 | 20.800 |
Why?
|
| Middle Aged | 374 | 2024 | 2108 | 20.740 |
Why?
|
| Male | 444 | 2024 | 3671 | 20.730 |
Why?
|
| Female | 431 | 2024 | 4060 | 19.340 |
Why?
|
| Aged | 322 | 2024 | 1539 | 19.050 |
Why?
|
| Risk Factors | 227 | 2024 | 767 | 14.860 |
Why?
|
| Glomerular Filtration Rate | 92 | 2024 | 115 | 14.160 |
Why?
|
| Cardiovascular Diseases | 71 | 2022 | 172 | 12.650 |
Why?
|
| United States | 167 | 2024 | 1019 | 11.860 |
Why?
|
| Dietary Proteins | 49 | 2024 | 53 | 11.820 |
Why?
|
| Cohort Studies | 137 | 2024 | 285 | 11.140 |
Why?
|
| Veterans | 49 | 2024 | 70 | 10.930 |
Why?
|
| Peritoneal Dialysis | 44 | 2024 | 48 | 10.900 |
Why?
|
| Inflammation | 63 | 2023 | 143 | 10.460 |
Why?
|
| Health Services Accessibility | 42 | 2024 | 145 | 10.390 |
Why?
|
| Nutritional Status | 52 | 2024 | 64 | 10.200 |
Why?
|
| Retrospective Studies | 120 | 2024 | 681 | 9.800 |
Why?
|
| Protein-Energy Malnutrition | 42 | 2024 | 42 | 9.710 |
Why?
|
| Phosphorus | 41 | 2024 | 43 | 9.520 |
Why?
|
| Biomarkers | 80 | 2024 | 214 | 9.490 |
Why?
|
| Quality of Life | 50 | 2024 | 184 | 9.440 |
Why?
|
| Body Mass Index | 62 | 2023 | 145 | 9.190 |
Why?
|
| Obesity | 53 | 2021 | 226 | 9.090 |
Why?
|
| Proportional Hazards Models | 113 | 2022 | 169 | 8.950 |
Why?
|
| Diabetic Nephropathies | 29 | 2022 | 56 | 8.920 |
Why?
|
| Diet, Protein-Restricted | 28 | 2024 | 28 | 8.790 |
Why?
|
| Adult | 173 | 2024 | 2113 | 8.020 |
Why?
|
| Treatment Outcome | 105 | 2024 | 500 | 7.340 |
Why?
|
| Cause of Death | 51 | 2020 | 82 | 7.280 |
Why?
|
| Diet | 32 | 2024 | 111 | 7.200 |
Why?
|
| Disease Progression | 79 | 2024 | 170 | 7.070 |
Why?
|
| Risk Assessment | 67 | 2024 | 197 | 6.890 |
Why?
|
| Acute Kidney Injury | 21 | 2022 | 27 | 6.750 |
Why?
|
| Hospitalization | 40 | 2021 | 128 | 6.710 |
Why?
|
| Time Factors | 78 | 2021 | 321 | 6.460 |
Why?
|
| Sarcopenia | 16 | 2024 | 19 | 6.450 |
Why?
|
| Prognosis | 83 | 2024 | 220 | 6.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 26 | 2022 | 279 | 6.010 |
Why?
|
| Alkaline Phosphatase | 24 | 2020 | 33 | 5.980 |
Why?
|
| Nutrition Therapy | 12 | 2024 | 13 | 5.900 |
Why?
|
| Caregivers | 13 | 2022 | 29 | 5.890 |
Why?
|
| Hypertension | 30 | 2022 | 147 | 5.890 |
Why?
|
| Hyperphosphatemia | 20 | 2024 | 20 | 5.800 |
Why?
|
| Aged, 80 and over | 80 | 2022 | 497 | 5.800 |
Why?
|
| Anemia | 25 | 2020 | 28 | 5.750 |
Why?
|
| Serum Albumin | 35 | 2023 | 50 | 5.570 |
Why?
|
| Hyperparathyroidism, Secondary | 21 | 2019 | 23 | 5.540 |
Why?
|
| Blood Glucose | 20 | 2024 | 188 | 5.480 |
Why?
|
| Renal Insufficiency | 14 | 2023 | 21 | 5.380 |
Why?
|
| Parathyroid Hormone | 33 | 2022 | 44 | 5.210 |
Why?
|
| Hyperkalemia | 13 | 2023 | 13 | 5.160 |
Why?
|
| Survival Rate | 65 | 2021 | 111 | 5.110 |
Why?
|
| Creatinine | 28 | 2024 | 48 | 5.070 |
Why?
|
| Blood Pressure | 25 | 2020 | 112 | 5.060 |
Why?
|
| Stroke | 15 | 2022 | 46 | 5.040 |
Why?
|
| Iron | 26 | 2023 | 35 | 4.980 |
Why?
|
| Hematinics | 18 | 2020 | 18 | 4.860 |
Why?
|
| Calcium | 24 | 2022 | 117 | 4.810 |
Why?
|
| Incidence | 47 | 2024 | 197 | 4.640 |
Why?
|
| Patient Participation | 10 | 2021 | 32 | 4.490 |
Why?
|
| Cachexia | 24 | 2023 | 25 | 4.390 |
Why?
|
| Heart Failure | 22 | 2023 | 49 | 4.380 |
Why?
|
| Metformin | 9 | 2020 | 35 | 4.320 |
Why?
|
| Survival Analysis | 53 | 2020 | 95 | 4.310 |
Why?
|
| Body Composition | 22 | 2024 | 47 | 4.300 |
Why?
|
| Erythropoietin | 22 | 2020 | 25 | 4.300 |
Why?
|
| Health Promotion | 25 | 2023 | 89 | 4.290 |
Why?
|
| Malnutrition | 26 | 2022 | 51 | 4.290 |
Why?
|
| Nutrition Assessment | 20 | 2023 | 26 | 4.190 |
Why?
|
| Hypothyroidism | 11 | 2024 | 48 | 4.170 |
Why?
|
| Hemoglobins | 22 | 2018 | 30 | 4.150 |
Why?
|
| Diabetes Mellitus | 24 | 2024 | 208 | 4.140 |
Why?
|
| Follow-Up Studies | 54 | 2024 | 268 | 4.130 |
Why?
|
| Uremia | 13 | 2022 | 15 | 4.120 |
Why?
|
| Nephrology | 22 | 2024 | 22 | 4.110 |
Why?
|
| Dietary Supplements | 21 | 2023 | 44 | 4.090 |
Why?
|
| Coronary Disease | 9 | 2018 | 18 | 3.960 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 13 | 2022 | 13 | 3.940 |
Why?
|
| Dietetics | 8 | 2024 | 8 | 3.900 |
Why?
|
| Phosphorus, Dietary | 15 | 2023 | 15 | 3.840 |
Why?
|
| Health Literacy | 19 | 2024 | 35 | 3.800 |
Why?
|
| Ferritins | 17 | 2017 | 17 | 3.790 |
Why?
|
| Gastrointestinal Microbiome | 8 | 2022 | 26 | 3.780 |
Why?
|
| Acidosis, Lactic | 8 | 2020 | 8 | 3.610 |
Why?
|
| Hemodialysis, Home | 9 | 2020 | 9 | 3.610 |
Why?
|
| Comorbidity | 47 | 2021 | 147 | 3.500 |
Why?
|
| Global Health | 24 | 2022 | 54 | 3.430 |
Why?
|
| Quinazolinones | 10 | 2021 | 10 | 3.400 |
Why?
|
| Coronary Artery Disease | 11 | 2022 | 85 | 3.360 |
Why?
|
| Ferric Compounds | 8 | 2024 | 8 | 3.310 |
Why?
|
| Hypoalbuminemia | 11 | 2019 | 13 | 3.230 |
Why?
|
| Renal Replacement Therapy | 19 | 2024 | 19 | 3.230 |
Why?
|
| Hyponatremia | 14 | 2023 | 20 | 3.180 |
Why?
|
| Ergocalciferols | 13 | 2019 | 13 | 3.160 |
Why?
|
| Phosphates | 10 | 2024 | 13 | 3.110 |
Why?
|
| Hypoglycemic Agents | 14 | 2021 | 165 | 3.090 |
Why?
|
| Prospective Studies | 42 | 2024 | 331 | 3.080 |
Why?
|
| Chronic Disease | 39 | 2022 | 167 | 3.060 |
Why?
|
| Nutritionists | 6 | 2024 | 6 | 3.050 |
Why?
|
| Vitamin D | 14 | 2022 | 45 | 3.030 |
Why?
|
| Precision Medicine | 6 | 2020 | 13 | 3.020 |
Why?
|
| Mortality | 15 | 2021 | 43 | 2.930 |
Why?
|
| Arteriovenous Shunt, Surgical | 8 | 2020 | 8 | 2.820 |
Why?
|
| Conservative Treatment | 7 | 2021 | 10 | 2.810 |
Why?
|
| Potassium, Dietary | 9 | 2022 | 9 | 2.800 |
Why?
|
| Muscle, Skeletal | 11 | 2024 | 75 | 2.790 |
Why?
|
| Graft Survival | 20 | 2020 | 36 | 2.680 |
Why?
|
| Hypoglycemia | 5 | 2023 | 30 | 2.660 |
Why?
|
| Potassium | 17 | 2024 | 26 | 2.650 |
Why?
|
| Diet, Vegetarian | 7 | 2021 | 7 | 2.620 |
Why?
|
| Brain Ischemia | 5 | 2018 | 10 | 2.500 |
Why?
|
| Kidney Function Tests | 23 | 2021 | 25 | 2.400 |
Why?
|
| Minerals | 10 | 2022 | 12 | 2.390 |
Why?
|
| Health Status Disparities | 11 | 2023 | 83 | 2.310 |
Why?
|
| Health Education | 23 | 2022 | 55 | 2.280 |
Why?
|
| Graft Rejection | 13 | 2020 | 26 | 2.270 |
Why?
|
| Depression | 8 | 2017 | 128 | 2.270 |
Why?
|
| Healthcare Disparities | 14 | 2024 | 83 | 2.270 |
Why?
|
| Wasting Syndrome | 8 | 2019 | 8 | 2.260 |
Why?
|
| Bicarbonates | 9 | 2021 | 16 | 2.240 |
Why?
|
| Age Factors | 30 | 2024 | 193 | 2.240 |
Why?
|
| Body Weight | 11 | 2021 | 90 | 2.190 |
Why?
|
| Adolescent | 36 | 2021 | 869 | 2.180 |
Why?
|
| Anemia, Iron-Deficiency | 11 | 2014 | 12 | 2.170 |
Why?
|
| Cholesterol, HDL | 11 | 2020 | 23 | 2.170 |
Why?
|
| Sucrose | 5 | 2024 | 13 | 2.150 |
Why?
|
| Predictive Value of Tests | 30 | 2021 | 127 | 2.150 |
Why?
|
| Energy Intake | 13 | 2018 | 30 | 2.100 |
Why?
|
| Albuminuria | 9 | 2023 | 31 | 2.050 |
Why?
|
| Urea | 13 | 2022 | 15 | 2.050 |
Why?
|
| Frailty | 5 | 2024 | 7 | 2.000 |
Why?
|
| Antihypertensive Agents | 12 | 2020 | 56 | 1.940 |
Why?
|
| Early Diagnosis | 16 | 2021 | 26 | 1.910 |
Why?
|
| Constipation | 4 | 2021 | 7 | 1.900 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 20 | 1.900 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 19 | 1.900 |
Why?
|
| Proteinuria | 7 | 2024 | 15 | 1.870 |
Why?
|
| Hypercalcemia | 7 | 2016 | 11 | 1.810 |
Why?
|
| Eating | 6 | 2018 | 31 | 1.800 |
Why?
|
| Diet, High-Protein | 3 | 2020 | 3 | 1.790 |
Why?
|
| Acidosis | 11 | 2020 | 30 | 1.790 |
Why?
|
| Bone Diseases | 5 | 2019 | 7 | 1.760 |
Why?
|
| Severity of Illness Index | 22 | 2024 | 118 | 1.760 |
Why?
|
| Logistic Models | 21 | 2023 | 165 | 1.740 |
Why?
|
| Overweight | 5 | 2014 | 30 | 1.730 |
Why?
|
| Exercise | 6 | 2021 | 55 | 1.720 |
Why?
|
| Coronary Artery Bypass | 4 | 2019 | 15 | 1.720 |
Why?
|
| Health Equity | 6 | 2024 | 24 | 1.710 |
Why?
|
| Chelating Agents | 9 | 2021 | 13 | 1.660 |
Why?
|
| Thyrotropin | 11 | 2024 | 51 | 1.650 |
Why?
|
| Prevalence | 29 | 2021 | 259 | 1.640 |
Why?
|
| Secondary Prevention | 11 | 2020 | 16 | 1.630 |
Why?
|
| Young Adult | 26 | 2020 | 567 | 1.620 |
Why?
|
| Surveys and Questionnaires | 18 | 2022 | 280 | 1.610 |
Why?
|
| Registries | 18 | 2020 | 63 | 1.600 |
Why?
|
| Weight Loss | 10 | 2021 | 35 | 1.580 |
Why?
|
| Hypotension | 6 | 2018 | 8 | 1.570 |
Why?
|
| Animals | 24 | 2024 | 1875 | 1.560 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2020 | 12 | 1.550 |
Why?
|
| Odds Ratio | 20 | 2019 | 82 | 1.550 |
Why?
|
| Primary Prevention | 9 | 2020 | 22 | 1.550 |
Why?
|
| Periodicals as Topic | 3 | 2024 | 12 | 1.530 |
Why?
|
| Veterans Health | 6 | 2018 | 9 | 1.530 |
Why?
|
| Diuretics | 5 | 2024 | 13 | 1.530 |
Why?
|
| Glomerulonephritis | 3 | 2022 | 4 | 1.520 |
Why?
|
| Ambulatory Care Facilities | 4 | 2024 | 25 | 1.520 |
Why?
|
| Patient Selection | 12 | 2020 | 40 | 1.500 |
Why?
|
| Sodium | 11 | 2023 | 43 | 1.490 |
Why?
|
| Weight Gain | 10 | 2023 | 28 | 1.490 |
Why?
|
| Postoperative Complications | 7 | 2019 | 109 | 1.480 |
Why?
|
| Longitudinal Studies | 21 | 2022 | 140 | 1.470 |
Why?
|
| Hyperthyroidism | 4 | 2024 | 18 | 1.460 |
Why?
|
| Epigenesis, Genetic | 4 | 2021 | 36 | 1.450 |
Why?
|
| Child | 32 | 2022 | 524 | 1.450 |
Why?
|
| Delayed Graft Function | 7 | 2012 | 7 | 1.450 |
Why?
|
| Nephrectomy | 5 | 2022 | 14 | 1.440 |
Why?
|
| Databases, Factual | 17 | 2021 | 81 | 1.430 |
Why?
|
| Multivariate Analysis | 19 | 2019 | 104 | 1.410 |
Why?
|
| Nutritional Requirements | 6 | 2018 | 6 | 1.410 |
Why?
|
| Hyperparathyroidism | 5 | 2016 | 7 | 1.400 |
Why?
|
| Ultrafiltration | 4 | 2020 | 4 | 1.400 |
Why?
|
| Health Care Costs | 6 | 2021 | 30 | 1.400 |
Why?
|
| Adipose Tissue | 8 | 2018 | 69 | 1.390 |
Why?
|
| Diabetes Complications | 5 | 2021 | 41 | 1.370 |
Why?
|
| Telemedicine | 2 | 2022 | 43 | 1.360 |
Why?
|
| Internationality | 6 | 2020 | 9 | 1.360 |
Why?
|
| C-Reactive Protein | 16 | 2013 | 36 | 1.360 |
Why?
|
| Medication Adherence | 5 | 2019 | 64 | 1.320 |
Why?
|
| Pandemics | 10 | 2022 | 87 | 1.310 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 18 | 1.290 |
Why?
|
| Calcitriol | 6 | 2021 | 18 | 1.270 |
Why?
|
| Triglycerides | 9 | 2023 | 58 | 1.270 |
Why?
|
| Nephritis, Hereditary | 2 | 2021 | 2 | 1.270 |
Why?
|
| Bone Diseases, Metabolic | 4 | 2014 | 7 | 1.260 |
Why?
|
| Patient Transfer | 4 | 2018 | 11 | 1.250 |
Why?
|
| Atherosclerosis | 6 | 2022 | 39 | 1.250 |
Why?
|
| Cholesterol, LDL | 8 | 2019 | 35 | 1.250 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 31 | 1.240 |
Why?
|
| Erythrocyte Indices | 3 | 2019 | 4 | 1.220 |
Why?
|
| Polycystic Kidney Diseases | 4 | 2013 | 6 | 1.200 |
Why?
|
| Hypernatremia | 4 | 2017 | 9 | 1.200 |
Why?
|
| Laxatives | 4 | 2021 | 4 | 1.200 |
Why?
|
| Vascular Access Devices | 3 | 2017 | 4 | 1.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2022 | 24 | 1.180 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 3 | 1.170 |
Why?
|
| Muscular Atrophy | 6 | 2023 | 9 | 1.170 |
Why?
|
| Receptors, Calcitriol | 6 | 2016 | 16 | 1.160 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2024 | 82 | 1.150 |
Why?
|
| Preventive Health Services | 6 | 2020 | 21 | 1.150 |
Why?
|
| Transitional Care | 3 | 2020 | 6 | 1.150 |
Why?
|
| Fractures, Bone | 3 | 2024 | 21 | 1.150 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2013 | 28 | 1.150 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2019 | 58 | 1.110 |
Why?
|
| Parenteral Nutrition | 3 | 2016 | 8 | 1.100 |
Why?
|
| Pruritus | 3 | 2024 | 4 | 1.100 |
Why?
|
| Proteins | 7 | 2020 | 41 | 1.100 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 19 | 1.080 |
Why?
|
| Models, Biological | 7 | 2017 | 64 | 1.080 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2020 | 42 | 1.080 |
Why?
|
| Antioxidants | 8 | 2023 | 37 | 1.070 |
Why?
|
| Dyslipidemias | 4 | 2018 | 18 | 1.070 |
Why?
|
| Aging | 6 | 2024 | 105 | 1.070 |
Why?
|
| Lipids | 6 | 2022 | 35 | 1.070 |
Why?
|
| Myocardial Infarction | 5 | 2020 | 46 | 1.070 |
Why?
|
| Living Donors | 6 | 2023 | 12 | 1.060 |
Why?
|
| Phytic Acid | 2 | 2024 | 2 | 1.060 |
Why?
|
| Muscle Strength | 4 | 2024 | 9 | 1.060 |
Why?
|
| Cross-Sectional Studies | 26 | 2022 | 506 | 1.060 |
Why?
|
| Vitamin D Deficiency | 6 | 2022 | 24 | 1.040 |
Why?
|
| Linear Models | 11 | 2019 | 41 | 1.030 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2020 | 6 | 1.020 |
Why?
|
| Mass Screening | 8 | 2020 | 116 | 1.020 |
Why?
|
| Bone Density Conservation Agents | 6 | 2012 | 8 | 1.020 |
Why?
|
| Nutrition Disorders | 5 | 2012 | 5 | 1.020 |
Why?
|
| Child, Preschool | 16 | 2020 | 258 | 1.020 |
Why?
|
| Vitamins | 6 | 2020 | 14 | 1.020 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2024 | 27 | 1.010 |
Why?
|
| Mean Platelet Volume | 2 | 2016 | 2 | 1.000 |
Why?
|
| Betacoronavirus | 4 | 2020 | 14 | 1.000 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2020 | 49 | 1.000 |
Why?
|
| Sex Factors | 13 | 2019 | 155 | 0.990 |
Why?
|
| Energy Metabolism | 7 | 2024 | 21 | 0.980 |
Why?
|
| Cystatin C | 3 | 2023 | 3 | 0.970 |
Why?
|
| Anxiety | 4 | 2015 | 35 | 0.960 |
Why?
|
| Hepatitis C | 4 | 2007 | 19 | 0.960 |
Why?
|
| Hypophosphatemia | 3 | 2023 | 5 | 0.960 |
Why?
|
| Propensity Score | 10 | 2019 | 14 | 0.950 |
Why?
|
| Obesity, Morbid | 3 | 2019 | 10 | 0.950 |
Why?
|
| Stroke Volume | 3 | 2021 | 20 | 0.940 |
Why?
|
| Blood Platelets | 4 | 2020 | 9 | 0.940 |
Why?
|
| Syndrome | 18 | 2022 | 32 | 0.940 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2013 | 7 | 0.940 |
Why?
|
| Hemodiafiltration | 3 | 2021 | 3 | 0.930 |
Why?
|
| Nephrologists | 3 | 2022 | 3 | 0.920 |
Why?
|
| Microbiota | 2 | 2023 | 8 | 0.920 |
Why?
|
| Polypharmacy | 4 | 2024 | 17 | 0.920 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2024 | 14 | 0.910 |
Why?
|
| Risk | 11 | 2020 | 43 | 0.910 |
Why?
|
| Dialysis Solutions | 6 | 2018 | 7 | 0.910 |
Why?
|
| Kidney Glomerulus | 2 | 2022 | 29 | 0.910 |
Why?
|
| Thinness | 2 | 2015 | 4 | 0.910 |
Why?
|
| Diet Records | 4 | 2021 | 6 | 0.900 |
Why?
|
| Down-Regulation | 5 | 2019 | 57 | 0.900 |
Why?
|
| United States Department of Veterans Affairs | 7 | 2020 | 25 | 0.890 |
Why?
|
| Hemodialysis Units, Hospital | 2 | 2021 | 2 | 0.890 |
Why?
|
| Case-Control Studies | 10 | 2020 | 108 | 0.890 |
Why?
|
| Models, Statistical | 7 | 2018 | 17 | 0.870 |
Why?
|
| Atrial Fibrillation | 3 | 2022 | 16 | 0.860 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 26 | 0.860 |
Why?
|
| Nutritional Sciences | 3 | 2024 | 4 | 0.860 |
Why?
|
| Disease Management | 8 | 2024 | 33 | 0.860 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2024 | 6 | 0.840 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2023 | 7 | 0.840 |
Why?
|
| Drug Combinations | 5 | 2024 | 20 | 0.840 |
Why?
|
| Fibroblast Growth Factors | 5 | 2023 | 10 | 0.840 |
Why?
|
| Infant | 12 | 2020 | 187 | 0.830 |
Why?
|
| Kidney Neoplasms | 2 | 2014 | 12 | 0.830 |
Why?
|
| Acute Coronary Syndrome | 5 | 2021 | 12 | 0.820 |
Why?
|
| Bone and Bones | 3 | 2023 | 16 | 0.820 |
Why?
|
| Oxidative Stress | 8 | 2016 | 102 | 0.820 |
Why?
|
| California | 13 | 2019 | 230 | 0.820 |
Why?
|
| Nanotechnology | 2 | 2021 | 4 | 0.810 |
Why?
|
| Patient Safety | 2 | 2021 | 10 | 0.810 |
Why?
|
| Lactic Acid | 2 | 2013 | 8 | 0.810 |
Why?
|
| Vascular Calcification | 3 | 2018 | 12 | 0.810 |
Why?
|
| Congresses as Topic | 6 | 2016 | 20 | 0.810 |
Why?
|
| Silicates | 2 | 2021 | 3 | 0.810 |
Why?
|
| Dysbiosis | 4 | 2023 | 10 | 0.810 |
Why?
|
| Polymers | 2 | 2021 | 7 | 0.810 |
Why?
|
| Hypocalcemia | 4 | 2010 | 5 | 0.800 |
Why?
|
| Hip Fractures | 4 | 2020 | 9 | 0.800 |
Why?
|
| Cerebrovascular Disorders | 3 | 2020 | 8 | 0.800 |
Why?
|
| Regression Analysis | 11 | 2013 | 66 | 0.800 |
Why?
|
| Health Policy | 10 | 2022 | 26 | 0.790 |
Why?
|
| Insulin Resistance | 6 | 2018 | 74 | 0.780 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 22 | 0.780 |
Why?
|
| Tissue Donors | 4 | 2022 | 14 | 0.780 |
Why?
|
| Longevity | 3 | 2021 | 7 | 0.780 |
Why?
|
| Seasons | 3 | 2022 | 7 | 0.770 |
Why?
|
| Solitary Kidney | 1 | 2022 | 1 | 0.770 |
Why?
|
| Central Venous Catheters | 2 | 2020 | 4 | 0.770 |
Why?
|
| Anthropometry | 11 | 2011 | 16 | 0.760 |
Why?
|
| Hemodynamics | 4 | 2020 | 34 | 0.760 |
Why?
|
| Absorptiometry, Photon | 11 | 2019 | 15 | 0.760 |
Why?
|
| Bone Density | 7 | 2019 | 25 | 0.750 |
Why?
|
| Naturopathy | 1 | 2022 | 1 | 0.750 |
Why?
|
| Nitrogen | 5 | 2016 | 6 | 0.750 |
Why?
|
| Uric Acid | 3 | 2022 | 4 | 0.750 |
Why?
|
| Nuts | 1 | 2022 | 1 | 0.750 |
Why?
|
| Societies, Scientific | 3 | 2018 | 3 | 0.740 |
Why?
|
| Diet, Vegan | 2 | 2019 | 2 | 0.740 |
Why?
|
| Magnesium | 3 | 2018 | 5 | 0.730 |
Why?
|
| Diet Therapy | 2 | 2019 | 3 | 0.730 |
Why?
|
| Cost-Benefit Analysis | 10 | 2020 | 48 | 0.720 |
Why?
|
| Meat | 2 | 2019 | 2 | 0.720 |
Why?
|
| Macular Edema | 1 | 2022 | 9 | 0.720 |
Why?
|
| Sensitivity and Specificity | 12 | 2016 | 98 | 0.720 |
Why?
|
| Transferrin | 8 | 2015 | 9 | 0.710 |
Why?
|
| Practice Guidelines as Topic | 8 | 2019 | 84 | 0.710 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 30 | 0.710 |
Why?
|
| Interleukin-6 | 11 | 2012 | 45 | 0.710 |
Why?
|
| Myocardial Revascularization | 2 | 2014 | 9 | 0.710 |
Why?
|
| Evidence-Based Medicine | 4 | 2012 | 28 | 0.700 |
Why?
|
| Patient Compliance | 4 | 2020 | 48 | 0.700 |
Why?
|
| Water-Electrolyte Imbalance | 3 | 2017 | 6 | 0.700 |
Why?
|
| Catheters, Indwelling | 4 | 2018 | 6 | 0.700 |
Why?
|
| Healthy Lifestyle | 1 | 2021 | 4 | 0.700 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 16 | 0.700 |
Why?
|
| Cannabis | 1 | 2021 | 9 | 0.700 |
Why?
|
| Consensus | 5 | 2024 | 39 | 0.690 |
Why?
|
| Lipoproteins, HDL | 3 | 2013 | 5 | 0.680 |
Why?
|
| Diabetic Retinopathy | 1 | 2022 | 52 | 0.680 |
Why?
|
| Cost of Illness | 1 | 2021 | 19 | 0.680 |
Why?
|
| Palliative Care | 2 | 2021 | 22 | 0.680 |
Why?
|
| Intestinal Diseases | 1 | 2021 | 1 | 0.680 |
Why?
|
| Calcifediol | 2 | 2022 | 2 | 0.680 |
Why?
|
| Models, Cardiovascular | 1 | 2021 | 5 | 0.680 |
Why?
|
| Diet, Sodium-Restricted | 3 | 2017 | 3 | 0.670 |
Why?
|
| Nutritional Support | 3 | 2022 | 4 | 0.670 |
Why?
|
| Quality Improvement | 1 | 2021 | 31 | 0.670 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 72 | 0.670 |
Why?
|
| Cerebral Arteries | 1 | 2020 | 1 | 0.670 |
Why?
|
| Patient Preference | 1 | 2021 | 11 | 0.670 |
Why?
|
| Prolyl-Hydroxylase Inhibitors | 1 | 2020 | 1 | 0.670 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 35 | 0.670 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 9 | 0.670 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2020 | 2 | 0.660 |
Why?
|
| Bone Remodeling | 4 | 2013 | 6 | 0.650 |
Why?
|
| Eosinophilia | 1 | 2020 | 3 | 0.650 |
Why?
|
| Eosinophils | 1 | 2020 | 4 | 0.650 |
Why?
|
| Biosensing Techniques | 1 | 2020 | 3 | 0.650 |
Why?
|
| Anticoagulants | 5 | 2022 | 14 | 0.640 |
Why?
|
| Societies, Medical | 6 | 2020 | 67 | 0.640 |
Why?
|
| Gastroenteritis | 1 | 2020 | 1 | 0.640 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2019 | 155 | 0.640 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2017 | 4 | 0.640 |
Why?
|
| Thrombocytosis | 2 | 2011 | 2 | 0.640 |
Why?
|
| Urogenital Abnormalities | 1 | 2020 | 1 | 0.640 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2020 | 2 | 0.640 |
Why?
|
| Laboratories | 1 | 2020 | 3 | 0.630 |
Why?
|
| Taboo | 1 | 2020 | 1 | 0.630 |
Why?
|
| Sweat | 1 | 2020 | 2 | 0.630 |
Why?
|
| Regional Blood Flow | 1 | 2019 | 17 | 0.620 |
Why?
|
| Urine | 2 | 2016 | 14 | 0.620 |
Why?
|
| Naphthalenes | 3 | 2009 | 5 | 0.610 |
Why?
|
| Restless Legs Syndrome | 2 | 2017 | 2 | 0.610 |
Why?
|
| Infant, Newborn | 13 | 2020 | 199 | 0.610 |
Why?
|
| Hypokalemia | 3 | 2019 | 7 | 0.610 |
Why?
|
| Patient-Centered Care | 2 | 2021 | 14 | 0.610 |
Why?
|
| Apolipoprotein L1 | 1 | 2019 | 1 | 0.600 |
Why?
|
| Inflammation Mediators | 4 | 2012 | 30 | 0.590 |
Why?
|
| Iron Compounds | 2 | 2009 | 7 | 0.590 |
Why?
|
| Withholding Treatment | 1 | 2019 | 2 | 0.590 |
Why?
|
| Prealbumin | 4 | 2011 | 4 | 0.590 |
Why?
|
| Vancomycin | 1 | 2019 | 5 | 0.590 |
Why?
|
| Health Resources | 2 | 2009 | 12 | 0.590 |
Why?
|
| Analysis of Variance | 9 | 2013 | 63 | 0.590 |
Why?
|
| Editorial Policies | 1 | 2019 | 1 | 0.590 |
Why?
|
| Genetic Variation | 1 | 2019 | 40 | 0.590 |
Why?
|
| Cholesterol | 5 | 2022 | 37 | 0.580 |
Why?
|
| Hemodialysis Solutions | 1 | 2018 | 1 | 0.580 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2018 | 2 | 0.580 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 8 | 0.580 |
Why?
|
| Keto Acids | 2 | 2016 | 2 | 0.580 |
Why?
|
| Blood Urea Nitrogen | 6 | 2020 | 6 | 0.570 |
Why?
|
| Platelet Count | 3 | 2017 | 6 | 0.570 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2021 | 20 | 0.560 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 73 | 0.560 |
Why?
|
| Preoperative Period | 2 | 2015 | 6 | 0.560 |
Why?
|
| Recombinant Proteins | 9 | 2017 | 45 | 0.560 |
Why?
|
| Renin | 3 | 2014 | 5 | 0.560 |
Why?
|
| Calcinosis | 4 | 2012 | 12 | 0.560 |
Why?
|
| Parathyroidectomy | 1 | 2018 | 3 | 0.560 |
Why?
|
| Thyroid Gland | 2 | 2017 | 28 | 0.560 |
Why?
|
| Hepacivirus | 3 | 2007 | 9 | 0.560 |
Why?
|
| ROC Curve | 5 | 2017 | 28 | 0.560 |
Why?
|
| Biological Products | 1 | 2018 | 6 | 0.550 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 7 | 0.550 |
Why?
|
| Bipolar Disorder | 1 | 2018 | 13 | 0.550 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 12 | 0.550 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 9 | 0.550 |
Why?
|
| Adiponectin | 2 | 2015 | 6 | 0.550 |
Why?
|
| Allografts | 4 | 2023 | 7 | 0.550 |
Why?
|
| Niacin | 2 | 2015 | 5 | 0.550 |
Why?
|
| Peritonitis | 1 | 2017 | 3 | 0.550 |
Why?
|
| Thyroid Diseases | 2 | 2017 | 25 | 0.550 |
Why?
|
| Biological Variation, Individual | 1 | 2017 | 1 | 0.550 |
Why?
|
| Canagliflozin | 1 | 2017 | 5 | 0.540 |
Why?
|
| Hypolipidemic Agents | 2 | 2015 | 13 | 0.540 |
Why?
|
| Diagnosis-Related Groups | 3 | 2013 | 3 | 0.540 |
Why?
|
| Neutrophils | 1 | 2017 | 14 | 0.540 |
Why?
|
| Lymphocytes | 1 | 2017 | 17 | 0.540 |
Why?
|
| Coronary Vessels | 3 | 2018 | 44 | 0.540 |
Why?
|
| Amino Acids | 5 | 2021 | 15 | 0.540 |
Why?
|
| Oleanolic Acid | 2 | 2018 | 2 | 0.540 |
Why?
|
| Dialysis | 4 | 2022 | 5 | 0.540 |
Why?
|
| Frail Elderly | 4 | 2024 | 9 | 0.540 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 1 | 0.540 |
Why?
|
| Dietary Fiber | 6 | 2023 | 9 | 0.530 |
Why?
|
| Lanthanum | 1 | 2017 | 7 | 0.530 |
Why?
|
| Administration, Intravenous | 5 | 2017 | 9 | 0.530 |
Why?
|
| Vitamin B 12 | 1 | 2017 | 1 | 0.530 |
Why?
|
| Folic Acid | 1 | 2017 | 3 | 0.530 |
Why?
|
| Serum Albumin, Human | 1 | 2017 | 1 | 0.530 |
Why?
|
| Global Burden of Disease | 4 | 2020 | 6 | 0.530 |
Why?
|
| Erythropoiesis | 3 | 2017 | 3 | 0.530 |
Why?
|
| Warfarin | 4 | 2022 | 7 | 0.520 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2011 | 48 | 0.520 |
Why?
|
| Dementia | 1 | 2017 | 14 | 0.510 |
Why?
|
| Nephrotic Syndrome | 1 | 2017 | 5 | 0.510 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 7 | 0.510 |
Why?
|
| Transition to Adult Care | 11 | 2016 | 23 | 0.500 |
Why?
|
| Albumins | 7 | 2022 | 10 | 0.500 |
Why?
|
| Double-Blind Method | 8 | 2024 | 101 | 0.500 |
Why?
|
| Patient Readmission | 5 | 2021 | 24 | 0.490 |
Why?
|
| Polyamines | 4 | 2010 | 6 | 0.490 |
Why?
|
| Comparative Effectiveness Research | 2 | 2015 | 4 | 0.490 |
Why?
|
| Pancreas Transplantation | 2 | 2013 | 3 | 0.480 |
Why?
|
| Phenotype | 4 | 2023 | 91 | 0.480 |
Why?
|
| Meat Products | 2 | 2014 | 2 | 0.470 |
Why?
|
| Models, Theoretical | 2 | 2012 | 15 | 0.470 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 1 | 0.460 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 64 | 0.460 |
Why?
|
| Body Height | 1 | 2015 | 5 | 0.450 |
Why?
|
| Intra-Abdominal Fat | 1 | 2015 | 5 | 0.450 |
Why?
|
| Subcutaneous Fat | 1 | 2015 | 4 | 0.450 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 4 | 0.450 |
Why?
|
| Length of Stay | 2 | 2015 | 53 | 0.450 |
Why?
|
| Diet, Reducing | 1 | 2015 | 4 | 0.450 |
Why?
|
| Sleep | 1 | 2015 | 14 | 0.450 |
Why?
|
| Nursing Homes | 2 | 2020 | 8 | 0.450 |
Why?
|
| Algorithms | 8 | 2021 | 83 | 0.450 |
Why?
|
| Patient Education as Topic | 6 | 2021 | 58 | 0.440 |
Why?
|
| Motor Activity | 2 | 2014 | 26 | 0.440 |
Why?
|
| Self Report | 1 | 2015 | 35 | 0.440 |
Why?
|
| Brachiocephalic Veins | 1 | 2014 | 1 | 0.440 |
Why?
|
| Brachial Artery | 1 | 2014 | 2 | 0.440 |
Why?
|
| Angioplasty, Balloon | 1 | 2014 | 2 | 0.440 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2014 | 3 | 0.440 |
Why?
|
| Interviews as Topic | 1 | 2015 | 77 | 0.440 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 5 | 0.440 |
Why?
|
| Population Surveillance | 2 | 2014 | 30 | 0.440 |
Why?
|
| Lymphocyte Count | 3 | 2017 | 6 | 0.440 |
Why?
|
| Cognition Disorders | 1 | 2014 | 19 | 0.430 |
Why?
|
| Insulin | 2 | 2021 | 146 | 0.430 |
Why?
|
| Geriatric Assessment | 4 | 2024 | 13 | 0.430 |
Why?
|
| Neoplasms | 3 | 2021 | 92 | 0.420 |
Why?
|
| Chemistry, Clinical | 1 | 2014 | 1 | 0.420 |
Why?
|
| Renal Elimination | 3 | 2019 | 3 | 0.420 |
Why?
|
| Altitude | 1 | 2014 | 3 | 0.420 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 2 | 0.410 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 10 | 0.410 |
Why?
|
| Intestinal Absorption | 2 | 2024 | 7 | 0.410 |
Why?
|
| Aldosterone | 2 | 2023 | 8 | 0.410 |
Why?
|
| Food, Formulated | 2 | 2011 | 4 | 0.410 |
Why?
|
| Life Style | 3 | 2023 | 51 | 0.410 |
Why?
|
| Toxins, Biological | 1 | 2013 | 1 | 0.410 |
Why?
|
| Reproducibility of Results | 7 | 2022 | 112 | 0.410 |
Why?
|
| Age Distribution | 6 | 2013 | 45 | 0.400 |
Why?
|
| Anorexia | 4 | 2013 | 8 | 0.400 |
Why?
|
| Outpatients | 4 | 2022 | 10 | 0.400 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 2 | 0.390 |
Why?
|
| Homeostasis | 3 | 2021 | 40 | 0.390 |
Why?
|
| Hypercholesterolemia | 3 | 2015 | 13 | 0.390 |
Why?
|
| Citrulline | 1 | 2013 | 10 | 0.390 |
Why?
|
| Osteoporosis | 4 | 2019 | 12 | 0.390 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 57 | 0.390 |
Why?
|
| Leptin | 4 | 2007 | 21 | 0.390 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2012 | 2 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 153 | 0.390 |
Why?
|
| Tight Junction Proteins | 1 | 2012 | 1 | 0.390 |
Why?
|
| Homocysteine | 4 | 2006 | 4 | 0.390 |
Why?
|
| Histocompatibility Testing | 1 | 2012 | 4 | 0.380 |
Why?
|
| Enterocytes | 1 | 2012 | 2 | 0.380 |
Why?
|
| Plasma | 1 | 2012 | 6 | 0.380 |
Why?
|
| Models, Structural | 1 | 2012 | 1 | 0.380 |
Why?
|
| Heart | 1 | 2012 | 25 | 0.380 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 17 | 0.380 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 8 | 0.380 |
Why?
|
| Treatment Failure | 4 | 2017 | 20 | 0.370 |
Why?
|
| Protein Deficiency | 1 | 2012 | 1 | 0.370 |
Why?
|
| Hospital Mortality | 3 | 2008 | 36 | 0.370 |
Why?
|
| Confidence Intervals | 3 | 2019 | 17 | 0.370 |
Why?
|
| Food Handling | 1 | 2012 | 1 | 0.370 |
Why?
|
| Ownership | 2 | 2009 | 2 | 0.370 |
Why?
|
| Diet, Mediterranean | 2 | 2023 | 4 | 0.370 |
Why?
|
| Ramipril | 1 | 2012 | 1 | 0.360 |
Why?
|
| Tetrazoles | 1 | 2012 | 2 | 0.360 |
Why?
|
| Valine | 1 | 2012 | 4 | 0.360 |
Why?
|
| Observation | 1 | 2012 | 3 | 0.360 |
Why?
|
| Socioeconomic Factors | 5 | 2020 | 197 | 0.360 |
Why?
|
| Postoperative Care | 1 | 2011 | 8 | 0.360 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 14 | 0.360 |
Why?
|
| Appetite | 2 | 2018 | 15 | 0.360 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 42 | 0.350 |
Why?
|
| Hemorrhage | 3 | 2022 | 23 | 0.350 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 3 | 0.350 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2011 | 5 | 0.350 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 13 | 0.350 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2011 | 6 | 0.350 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 2013 | 2 | 0.350 |
Why?
|
| Phosphorus Metabolism Disorders | 2 | 2013 | 2 | 0.340 |
Why?
|
| Egg White | 1 | 2011 | 1 | 0.340 |
Why?
|
| Hallucinogens | 2 | 2013 | 7 | 0.340 |
Why?
|
| Health Priorities | 2 | 2021 | 6 | 0.340 |
Why?
|
| Observational Studies as Topic | 4 | 2018 | 9 | 0.340 |
Why?
|
| Glucose | 3 | 2023 | 50 | 0.340 |
Why?
|
| Probiotics | 2 | 2021 | 10 | 0.340 |
Why?
|
| Cyclonic Storms | 2 | 2022 | 2 | 0.330 |
Why?
|
| Arm | 1 | 2010 | 7 | 0.330 |
Why?
|
| Endocannabinoids | 2 | 2021 | 4 | 0.330 |
Why?
|
| Blood Pressure Determination | 3 | 2017 | 9 | 0.330 |
Why?
|
| Infrared Rays | 2 | 2001 | 2 | 0.320 |
Why?
|
| Sodium Bicarbonate | 1 | 2010 | 1 | 0.320 |
Why?
|
| Health Status | 6 | 2018 | 83 | 0.320 |
Why?
|
| Counseling | 1 | 2010 | 29 | 0.310 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 15 | 0.310 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2009 | 2 | 0.310 |
Why?
|
| Mental Disorders | 1 | 2010 | 60 | 0.310 |
Why?
|
| Aspartate Aminotransferases | 4 | 2015 | 6 | 0.300 |
Why?
|
| Receptors, CCR5 | 1 | 2009 | 2 | 0.300 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2011 | 7 | 0.300 |
Why?
|
| Waist Circumference | 5 | 2018 | 8 | 0.300 |
Why?
|
| Body Fluids | 1 | 2009 | 8 | 0.300 |
Why?
|
| Thyroid Function Tests | 4 | 2019 | 17 | 0.290 |
Why?
|
| Recommended Dietary Allowances | 2 | 2019 | 2 | 0.290 |
Why?
|
| Hepatitis C Antibodies | 2 | 2005 | 2 | 0.290 |
Why?
|
| Immunoenzyme Techniques | 2 | 2005 | 14 | 0.290 |
Why?
|
| Pediatrics | 4 | 2016 | 39 | 0.290 |
Why?
|
| Renin-Angiotensin System | 4 | 2023 | 7 | 0.290 |
Why?
|
| Cardiovascular Agents | 2 | 2021 | 4 | 0.280 |
Why?
|
| Chronic Pain | 2 | 2020 | 12 | 0.280 |
Why?
|
| Nephritis | 1 | 2008 | 1 | 0.280 |
Why?
|
| Drugs, Investigational | 1 | 2008 | 2 | 0.280 |
Why?
|
| Drug Design | 1 | 2008 | 7 | 0.280 |
Why?
|
| Muscle Proteins | 2 | 2023 | 13 | 0.280 |
Why?
|
| Health Expenditures | 4 | 2020 | 16 | 0.280 |
Why?
|
| Time-to-Treatment | 3 | 2018 | 8 | 0.270 |
Why?
|
| Poverty | 2 | 2021 | 64 | 0.270 |
Why?
|
| Forecasting | 3 | 2021 | 19 | 0.270 |
Why?
|
| Systole | 3 | 2020 | 7 | 0.270 |
Why?
|
| Food Preservatives | 3 | 2013 | 3 | 0.270 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2008 | 15 | 0.270 |
Why?
|
| Serum Amyloid P-Component | 1 | 2007 | 1 | 0.270 |
Why?
|
| Biopsy | 2 | 2021 | 36 | 0.260 |
Why?
|
| Myocardial Ischemia | 3 | 2016 | 9 | 0.260 |
Why?
|
| Epidemiologic Methods | 2 | 2004 | 4 | 0.260 |
Why?
|
| Electric Impedance | 3 | 2012 | 6 | 0.260 |
Why?
|
| Amino Acids, Essential | 2 | 2017 | 2 | 0.260 |
Why?
|
| Transplantation, Homologous | 2 | 2020 | 16 | 0.250 |
Why?
|
| Quality of Health Care | 3 | 2021 | 27 | 0.250 |
Why?
|
| Peroxidase | 1 | 2006 | 3 | 0.250 |
Why?
|
| Calcium Metabolism Disorders | 1 | 2006 | 1 | 0.250 |
Why?
|
| Patient Care | 2 | 2023 | 5 | 0.240 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2018 | 31 | 0.240 |
Why?
|
| Acid-Base Equilibrium | 1 | 2005 | 4 | 0.240 |
Why?
|
| Interleukin-8 | 1 | 2006 | 10 | 0.240 |
Why?
|
| Apolipoprotein A-I | 3 | 2019 | 3 | 0.240 |
Why?
|
| Recurrence | 3 | 2021 | 55 | 0.240 |
Why?
|
| Meals | 2 | 2018 | 2 | 0.240 |
Why?
|
| Calcimimetic Agents | 2 | 2018 | 2 | 0.230 |
Why?
|
| Plant Proteins | 2 | 2023 | 3 | 0.230 |
Why?
|
| Gene Amplification | 1 | 2005 | 3 | 0.230 |
Why?
|
| Micronutrients | 3 | 2022 | 4 | 0.230 |
Why?
|
| Waiting Lists | 3 | 2021 | 8 | 0.230 |
Why?
|
| RNA, Viral | 1 | 2005 | 20 | 0.230 |
Why?
|
| Trace Elements | 2 | 2015 | 2 | 0.230 |
Why?
|
| Drug Resistance | 3 | 2015 | 16 | 0.230 |
Why?
|
| Cells, Cultured | 2 | 2018 | 234 | 0.230 |
Why?
|
| Fatigue | 2 | 2022 | 7 | 0.230 |
Why?
|
| Developing Countries | 6 | 2021 | 38 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 63 | 0.230 |
Why?
|
| Coronary Vasospasm | 2 | 2016 | 2 | 0.230 |
Why?
|
| Sevelamer | 4 | 2010 | 4 | 0.220 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2021 | 4 | 0.220 |
Why?
|
| Health Personnel | 5 | 2022 | 49 | 0.220 |
Why?
|
| Hawaii | 3 | 2017 | 6 | 0.220 |
Why?
|
| Nutrition Policy | 2 | 2018 | 6 | 0.220 |
Why?
|
| Intensive Care Units | 2 | 2021 | 17 | 0.220 |
Why?
|
| Population Health | 1 | 2024 | 7 | 0.220 |
Why?
|
| Leadership | 2 | 2023 | 22 | 0.220 |
Why?
|
| Public Health | 2 | 2023 | 40 | 0.220 |
Why?
|
| Educational Status | 2 | 2022 | 61 | 0.220 |
Why?
|
| Safety-net Providers | 1 | 2024 | 24 | 0.220 |
Why?
|
| Protective Factors | 3 | 2020 | 7 | 0.220 |
Why?
|
| Pilot Projects | 4 | 2021 | 89 | 0.210 |
Why?
|
| Thrombosis | 2 | 2022 | 13 | 0.210 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2016 | 5 | 0.210 |
Why?
|
| Prebiotics | 2 | 2021 | 3 | 0.210 |
Why?
|
| Catheterization, Central Venous | 2 | 2016 | 6 | 0.210 |
Why?
|
| Republic of Korea | 4 | 2020 | 4 | 0.210 |
Why?
|
| Necrosis | 1 | 2024 | 30 | 0.210 |
Why?
|
| Polymorphism, Genetic | 3 | 2009 | 9 | 0.210 |
Why?
|
| Glycemic Index | 2 | 2016 | 4 | 0.210 |
Why?
|
| Body Size | 3 | 2013 | 8 | 0.210 |
Why?
|
| Demography | 2 | 2016 | 26 | 0.210 |
Why?
|
| Transplant Recipients | 2 | 2020 | 4 | 0.210 |
Why?
|
| Sex Distribution | 4 | 2013 | 44 | 0.210 |
Why?
|
| Immunomodulation | 2 | 2020 | 3 | 0.210 |
Why?
|
| Antiviral Agents | 2 | 2021 | 53 | 0.210 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2023 | 1 | 0.210 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 15 | 0.210 |
Why?
|
| Decision Making | 1 | 2023 | 25 | 0.210 |
Why?
|
| Europe | 2 | 2017 | 15 | 0.200 |
Why?
|
| Asthma | 1 | 2004 | 31 | 0.200 |
Why?
|
| Cytokines | 3 | 2011 | 80 | 0.200 |
Why?
|
| Hospitals, Proprietary | 1 | 2003 | 1 | 0.200 |
Why?
|
| Hospitals, Voluntary | 1 | 2003 | 1 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2014 | 52 | 0.200 |
Why?
|
| Tertiary Prevention | 2 | 2020 | 2 | 0.200 |
Why?
|
| Quality Indicators, Health Care | 1 | 2003 | 7 | 0.200 |
Why?
|
| National Health Programs | 2 | 2020 | 3 | 0.200 |
Why?
|
| Annual Reports as Topic | 3 | 2018 | 3 | 0.200 |
Why?
|
| Medicare | 2 | 2023 | 57 | 0.200 |
Why?
|
| Epoetin Alfa | 2 | 2017 | 2 | 0.200 |
Why?
|
| Los Angeles | 3 | 2010 | 321 | 0.200 |
Why?
|
| Program Development | 1 | 2023 | 34 | 0.200 |
Why?
|
| Critical Illness | 1 | 2003 | 14 | 0.190 |
Why?
|
| Animal Feed | 1 | 2023 | 11 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 11 | 0.190 |
Why?
|
| Fruit | 2 | 2023 | 10 | 0.190 |
Why?
|
| Metabolic Syndrome | 1 | 2023 | 35 | 0.190 |
Why?
|
| Pregnancy | 2 | 2022 | 599 | 0.190 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2014 | 16 | 0.190 |
Why?
|
| Russia | 1 | 2022 | 3 | 0.190 |
Why?
|
| Social Media | 1 | 2022 | 13 | 0.190 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2022 | 1 | 0.180 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 2 | 0.180 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 2 | 0.180 |
Why?
|
| Brassica | 1 | 2022 | 1 | 0.180 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2022 | 1 | 0.180 |
Why?
|
| Saliva | 1 | 2022 | 7 | 0.180 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2022 | 4 | 0.180 |
Why?
|
| Health Information Systems | 1 | 2021 | 2 | 0.180 |
Why?
|
| Age of Onset | 6 | 2016 | 16 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 6 | 0.180 |
Why?
|
| Muscles | 1 | 2021 | 19 | 0.180 |
Why?
|
| Athletes | 1 | 2022 | 7 | 0.180 |
Why?
|
| Genetic Testing | 1 | 2021 | 50 | 0.180 |
Why?
|
| Glucosides | 1 | 2021 | 6 | 0.180 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 4 | 0.180 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 13 | 0.180 |
Why?
|
| Vascular Diseases | 1 | 2021 | 10 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2019 | 14 | 0.170 |
Why?
|
| North Carolina | 1 | 2021 | 4 | 0.170 |
Why?
|
| Administration, Oral | 2 | 2016 | 54 | 0.170 |
Why?
|
| Nurses | 1 | 2021 | 8 | 0.170 |
Why?
|
| Drug Approval | 2 | 2020 | 6 | 0.170 |
Why?
|
| Ethanolamines | 1 | 2021 | 2 | 0.170 |
Why?
|
| Palmitic Acids | 1 | 2021 | 2 | 0.170 |
Why?
|
| Autopsy | 1 | 2021 | 3 | 0.170 |
Why?
|
| Oleic Acids | 1 | 2021 | 3 | 0.170 |
Why?
|
| Amides | 1 | 2021 | 4 | 0.170 |
Why?
|
| Anemia, Hypochromic | 1 | 2021 | 1 | 0.170 |
Why?
|
| Maltose | 1 | 2021 | 1 | 0.170 |
Why?
|
| Osteomalacia | 1 | 2021 | 1 | 0.170 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 21 | 0.170 |
Why?
|
| Infusions, Parenteral | 1 | 2021 | 7 | 0.170 |
Why?
|
| Malabsorption Syndromes | 1 | 2021 | 3 | 0.170 |
Why?
|
| Nephritis, Interstitial | 1 | 2021 | 6 | 0.170 |
Why?
|
| Patient Advocacy | 1 | 2021 | 8 | 0.170 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2021 | 1 | 0.170 |
Why?
|
| Family Health | 1 | 2021 | 8 | 0.170 |
Why?
|
| Synbiotics | 1 | 2021 | 3 | 0.170 |
Why?
|
| Disasters | 1 | 2021 | 4 | 0.170 |
Why?
|
| Family | 1 | 2021 | 27 | 0.170 |
Why?
|
| Patient Admission | 1 | 2021 | 10 | 0.170 |
Why?
|
| Compassionate Use Trials | 1 | 2020 | 3 | 0.170 |
Why?
|
| Machine Learning | 1 | 2021 | 12 | 0.170 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 10 | 0.170 |
Why?
|
| Hypertension, Renal | 1 | 2020 | 4 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 3 | 0.170 |
Why?
|
| Attitude to Health | 1 | 2021 | 46 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2020 | 7 | 0.170 |
Why?
|
| Germany | 2 | 2013 | 3 | 0.170 |
Why?
|
| Morbidity | 5 | 2019 | 21 | 0.170 |
Why?
|
| Opiate Alkaloids | 1 | 2020 | 3 | 0.160 |
Why?
|
| Guidelines as Topic | 2 | 2010 | 19 | 0.160 |
Why?
|
| Sodium, Dietary | 2 | 2018 | 3 | 0.160 |
Why?
|
| Neuroimmunomodulation | 1 | 2020 | 4 | 0.160 |
Why?
|
| Diet, Ketogenic | 1 | 2020 | 1 | 0.160 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2020 | 12 | 0.160 |
Why?
|
| Cognition | 1 | 2020 | 30 | 0.160 |
Why?
|
| Neurosecretory Systems | 1 | 2020 | 8 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 3 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 19 | 0.160 |
Why?
|
| Travel-Related Illness | 1 | 2020 | 1 | 0.160 |
Why?
|
| Insurance Benefits | 1 | 2020 | 2 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 54 | 0.160 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2020 | 3 | 0.160 |
Why?
|
| Glycerides | 1 | 2020 | 3 | 0.160 |
Why?
|
| Arachidonic Acids | 1 | 2020 | 8 | 0.160 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 6 | 0.160 |
Why?
|
| Markov Chains | 1 | 2019 | 3 | 0.160 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2020 | 17 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 8 | 0.160 |
Why?
|
| Delayed-Action Preparations | 1 | 2019 | 8 | 0.160 |
Why?
|
| Muscle Weakness | 1 | 2019 | 3 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2019 | 1 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2019 | 14 | 0.160 |
Why?
|
| Income | 1 | 2020 | 30 | 0.160 |
Why?
|
| Aryldialkylphosphatase | 1 | 2019 | 1 | 0.160 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2019 | 2 | 0.160 |
Why?
|
| Hyperglycemia | 2 | 2011 | 27 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 58 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 1 | 0.160 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2013 | 34 | 0.150 |
Why?
|
| Virginia | 2 | 2011 | 3 | 0.150 |
Why?
|
| Hemochromatosis | 1 | 1999 | 1 | 0.150 |
Why?
|
| Iron Overload | 1 | 1999 | 1 | 0.150 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 10 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 16 | 0.150 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 67 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 1 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 5 | 0.150 |
Why?
|
| Hand Strength | 3 | 2021 | 4 | 0.150 |
Why?
|
| Information Systems | 2 | 2016 | 11 | 0.150 |
Why?
|
| Health Care Surveys | 2 | 2022 | 28 | 0.150 |
Why?
|
| Linezolid | 1 | 2019 | 1 | 0.150 |
Why?
|
| Daptomycin | 1 | 2019 | 2 | 0.150 |
Why?
|
| Internet | 2 | 2020 | 25 | 0.150 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 17 | 0.150 |
Why?
|
| Protein Domains | 1 | 2018 | 1 | 0.150 |
Why?
|
| Calcification, Physiologic | 1 | 2018 | 1 | 0.150 |
Why?
|
| Epigenomics | 1 | 2018 | 2 | 0.150 |
Why?
|
| Sleep Aids, Pharmaceutical | 1 | 2018 | 1 | 0.150 |
Why?
|
| Binding Sites | 1 | 2018 | 24 | 0.150 |
Why?
|
| Acid-Base Imbalance | 1 | 2018 | 2 | 0.150 |
Why?
|
| Computational Biology | 1 | 2018 | 13 | 0.150 |
Why?
|
| Body Constitution | 2 | 2011 | 2 | 0.150 |
Why?
|
| Cell Transdifferentiation | 1 | 2018 | 8 | 0.150 |
Why?
|
| Water-Electrolyte Balance | 1 | 2018 | 15 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 22 | 0.140 |
Why?
|
| Smoking Cessation | 1 | 2018 | 25 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2018 | 21 | 0.140 |
Why?
|
| Retinal Perforations | 1 | 2018 | 1 | 0.140 |
Why?
|
| Biometry | 1 | 2018 | 3 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2018 | 53 | 0.140 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2018 | 27 | 0.140 |
Why?
|
| Food Additives | 3 | 2016 | 3 | 0.140 |
Why?
|
| Stress, Physiological | 1 | 2018 | 19 | 0.140 |
Why?
|
| Dietary Fats | 2 | 2010 | 19 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 32 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2018 | 190 | 0.140 |
Why?
|
| Urine Specimen Collection | 1 | 2018 | 1 | 0.140 |
Why?
|
| Up-Regulation | 3 | 2017 | 94 | 0.140 |
Why?
|
| Vegetables | 1 | 2018 | 8 | 0.140 |
Why?
|
| Diabetic Neuropathies | 1 | 2018 | 3 | 0.140 |
Why?
|
| Urodynamics | 1 | 2018 | 4 | 0.140 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 71 | 0.140 |
Why?
|
| Survivors | 1 | 2017 | 15 | 0.140 |
Why?
|
| Tendon Injuries | 1 | 1997 | 1 | 0.130 |
Why?
|
| Thoracic Vertebrae | 1 | 2017 | 2 | 0.130 |
Why?
|
| Knee Injuries | 1 | 1997 | 4 | 0.130 |
Why?
|
| Deceleration | 1 | 2017 | 2 | 0.130 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 7 | 0.130 |
Why?
|
| Physical Fitness | 2 | 2015 | 4 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2017 | 9 | 0.130 |
Why?
|
| Leukocyte Count | 2 | 2009 | 10 | 0.130 |
Why?
|
| Data Mining | 1 | 2017 | 4 | 0.130 |
Why?
|
| Testosterone | 1 | 2017 | 50 | 0.130 |
Why?
|
| Laparoscopy | 1 | 2017 | 21 | 0.130 |
Why?
|
| Hospitals, University | 1 | 2017 | 4 | 0.130 |
Why?
|
| Kinetics | 1 | 2017 | 69 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 33 | 0.130 |
Why?
|
| Commerce | 1 | 2017 | 4 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2017 | 6 | 0.130 |
Why?
|
| Megestrol Acetate | 2 | 2008 | 2 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2017 | 8 | 0.130 |
Why?
|
| Drug Industry | 1 | 2017 | 5 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2017 | 13 | 0.130 |
Why?
|
| Inpatients | 1 | 2017 | 22 | 0.130 |
Why?
|
| Cheese | 1 | 2016 | 1 | 0.130 |
Why?
|
| Plants, Edible | 1 | 2016 | 2 | 0.130 |
Why?
|
| Taiwan | 1 | 2016 | 4 | 0.130 |
Why?
|
| Activities of Daily Living | 2 | 2014 | 19 | 0.130 |
Why?
|
| Confusion | 2 | 2013 | 3 | 0.130 |
Why?
|
| Poisson Distribution | 3 | 2012 | 3 | 0.120 |
Why?
|
| Mental Health | 1 | 2017 | 70 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2016 | 10 | 0.120 |
Why?
|
| Swine | 2 | 2016 | 8 | 0.120 |
Why?
|
| Phosphate-Binding Proteins | 2 | 2014 | 2 | 0.120 |
Why?
|
| Aminoglycosides | 1 | 2016 | 2 | 0.120 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2016 | 2 | 0.120 |
Why?
|
| Electrolytes | 1 | 2016 | 5 | 0.120 |
Why?
|
| Cyprinidae | 1 | 2016 | 1 | 0.120 |
Why?
|
| United Kingdom | 3 | 2023 | 7 | 0.120 |
Why?
|
| Diastole | 1 | 2016 | 4 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2016 | 34 | 0.120 |
Why?
|
| Anabolic Agents | 2 | 2013 | 2 | 0.120 |
Why?
|
| Contrast Media | 1 | 2016 | 18 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 36 | 0.120 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2016 | 1 | 0.120 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 4 | 0.120 |
Why?
|
| Appetite Stimulants | 3 | 2013 | 4 | 0.120 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 5 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 25 | 0.120 |
Why?
|
| Skinfold Thickness | 2 | 2010 | 3 | 0.120 |
Why?
|
| Goals | 1 | 2016 | 8 | 0.120 |
Why?
|
| Smoking | 2 | 2018 | 86 | 0.120 |
Why?
|
| Long Term Adverse Effects | 1 | 2015 | 2 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 5 | 0.120 |
Why?
|
| Peritoneum | 1 | 2015 | 4 | 0.120 |
Why?
|
| Patient Care Bundles | 1 | 2015 | 2 | 0.120 |
Why?
|
| Drug Labeling | 1 | 2015 | 3 | 0.120 |
Why?
|
| Awards and Prizes | 1 | 2015 | 3 | 0.120 |
Why?
|
| Florida | 1 | 2015 | 1 | 0.120 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 2 | 0.120 |
Why?
|
| New Jersey | 1 | 2015 | 4 | 0.120 |
Why?
|
| Texas | 1 | 2015 | 9 | 0.120 |
Why?
|
| New York | 1 | 2015 | 7 | 0.120 |
Why?
|
| Gluconeogenesis | 1 | 2015 | 4 | 0.110 |
Why?
|
| Tissue and Organ Procurement | 2 | 2014 | 15 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2015 | 15 | 0.110 |
Why?
|
| Physical Endurance | 1 | 2015 | 1 | 0.110 |
Why?
|
| Developed Countries | 3 | 2020 | 7 | 0.110 |
Why?
|
| Exercise Test | 1 | 2015 | 9 | 0.110 |
Why?
|
| Cross Infection | 1 | 2015 | 12 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 30 | 0.110 |
Why?
|
| Ultraviolet Rays | 1 | 2014 | 4 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2014 | 5 | 0.110 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 9 | 0.110 |
Why?
|
| Myelinolysis, Central Pontine | 1 | 2014 | 1 | 0.110 |
Why?
|
| Clinical Coding | 1 | 2014 | 2 | 0.110 |
Why?
|
| Stents | 1 | 2014 | 13 | 0.110 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2014 | 13 | 0.110 |
Why?
|
| Calcium Oxalate | 1 | 2014 | 1 | 0.110 |
Why?
|
| Hyperoxaluria | 1 | 2014 | 1 | 0.110 |
Why?
|
| Kidney Calculi | 1 | 2014 | 1 | 0.110 |
Why?
|
| Molecular Structure | 1 | 2014 | 8 | 0.110 |
Why?
|
| Spectrophotometry | 1 | 2014 | 2 | 0.110 |
Why?
|
| Access to Information | 1 | 2014 | 4 | 0.100 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 7 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2014 | 8 | 0.100 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 1994 | 3 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 1994 | 6 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 17 | 0.100 |
Why?
|
| Brain | 1 | 2014 | 94 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2014 | 18 | 0.100 |
Why?
|
| Receptors, Angiotensin | 1 | 2013 | 4 | 0.100 |
Why?
|
| Triiodothyronine | 1 | 2014 | 54 | 0.100 |
Why?
|
| Molecular Weight | 1 | 2013 | 7 | 0.100 |
Why?
|
| Leukocytes | 1 | 2013 | 9 | 0.100 |
Why?
|
| Darbepoetin alfa | 2 | 2011 | 2 | 0.100 |
Why?
|
| Workload | 1 | 2013 | 6 | 0.100 |
Why?
|
| Vomiting | 1 | 2013 | 4 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2013 | 15 | 0.100 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2013 | 1 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2013 | 17 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2013 | 38 | 0.100 |
Why?
|
| Population Groups | 1 | 2013 | 5 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 79 | 0.100 |
Why?
|
| Spasm | 1 | 2013 | 1 | 0.100 |
Why?
|
| Sulfonic Acids | 1 | 2013 | 1 | 0.100 |
Why?
|
| Acetyl-CoA C-Acetyltransferase | 1 | 2013 | 2 | 0.100 |
Why?
|
| Acetamides | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2013 | 2 | 0.100 |
Why?
|
| Quinolines | 1 | 2013 | 2 | 0.100 |
Why?
|
| Acetates | 1 | 2013 | 6 | 0.100 |
Why?
|
| Protein Binding | 1 | 2013 | 29 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2013 | 17 | 0.100 |
Why?
|
| PPAR alpha | 1 | 2013 | 9 | 0.100 |
Why?
|
| Urban Population | 1 | 2013 | 85 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2012 | 7 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 21 | 0.100 |
Why?
|
| Pancreas | 1 | 2013 | 144 | 0.090 |
Why?
|
| Steroids | 1 | 2012 | 8 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2012 | 46 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2009 | 22 | 0.090 |
Why?
|
| Desiccation | 1 | 2012 | 1 | 0.090 |
Why?
|
| Food Preservation | 1 | 2012 | 1 | 0.090 |
Why?
|
| Italy | 1 | 2012 | 2 | 0.090 |
Why?
|
| Donor Selection | 1 | 2012 | 2 | 0.090 |
Why?
|
| Valsartan | 1 | 2012 | 1 | 0.090 |
Why?
|
| Selection Bias | 1 | 2011 | 1 | 0.090 |
Why?
|
| Mortality, Premature | 1 | 2011 | 4 | 0.090 |
Why?
|
| Roma | 1 | 2011 | 1 | 0.090 |
Why?
|
| Pancreatitis | 1 | 2013 | 108 | 0.090 |
Why?
|
| Particle Size | 1 | 2011 | 2 | 0.090 |
Why?
|
| Endotoxins | 1 | 2011 | 2 | 0.090 |
Why?
|
| Hyperaldosteronism | 1 | 2011 | 2 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2011 | 26 | 0.090 |
Why?
|
| Mobility Limitation | 1 | 2011 | 2 | 0.090 |
Why?
|
| Echocardiography, Doppler | 1 | 2011 | 1 | 0.090 |
Why?
|
| Risk Adjustment | 1 | 2011 | 1 | 0.090 |
Why?
|
| Organ Size | 1 | 2011 | 31 | 0.090 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2010 | 4 | 0.080 |
Why?
|
| Creatine | 1 | 2010 | 1 | 0.080 |
Why?
|
| Israel | 1 | 2010 | 5 | 0.080 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 4 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2010 | 7 | 0.080 |
Why?
|
| Radiology, Interventional | 1 | 2010 | 2 | 0.080 |
Why?
|
| Catheterization | 1 | 2010 | 7 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2010 | 25 | 0.080 |
Why?
|
| Occupational Exposure | 1 | 2010 | 12 | 0.080 |
Why?
|
| Off-Label Use | 1 | 2010 | 3 | 0.080 |
Why?
|
| Cost Sharing | 2 | 2020 | 3 | 0.080 |
Why?
|
| Diet Surveys | 1 | 2010 | 2 | 0.080 |
Why?
|
| Costs and Cost Analysis | 2 | 2020 | 16 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2010 | 27 | 0.080 |
Why?
|
| Transplantation | 1 | 2010 | 3 | 0.080 |
Why?
|
| Fructosamine | 1 | 2010 | 3 | 0.080 |
Why?
|
| Patient Care Team | 2 | 2020 | 13 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 19 | 0.080 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 9 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 84 | 0.080 |
Why?
|
| Chelation Therapy | 1 | 2009 | 1 | 0.080 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 3 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2009 | 8 | 0.080 |
Why?
|
| Drug Costs | 1 | 2009 | 11 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2009 | 21 | 0.080 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2009 | 1 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 19 | 0.070 |
Why?
|
| Australia | 1 | 2009 | 16 | 0.070 |
Why?
|
| Blood Volume | 1 | 2009 | 8 | 0.070 |
Why?
|
| Edema | 1 | 2009 | 6 | 0.070 |
Why?
|
| Pentoxifylline | 1 | 2008 | 3 | 0.070 |
Why?
|
| Free Radical Scavengers | 1 | 2008 | 2 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2008 | 26 | 0.070 |
Why?
|
| Interleukin-15 | 1 | 2008 | 2 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 9 | 0.070 |
Why?
|
| Interleukin-18 | 1 | 2008 | 8 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2008 | 12 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 25 | 0.070 |
Why?
|
| Heart Failure, Systolic | 1 | 2008 | 2 | 0.070 |
Why?
|
| Epidemiologic Factors | 1 | 2007 | 1 | 0.070 |
Why?
|
| Hematocrit | 1 | 2007 | 12 | 0.070 |
Why?
|
| Observer Variation | 1 | 2007 | 11 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 1 | 2007 | 10 | 0.070 |
Why?
|
| Cuba | 1 | 2007 | 2 | 0.070 |
Why?
|
| International Agencies | 1 | 2007 | 3 | 0.070 |
Why?
|
| Health Surveys | 1 | 2007 | 75 | 0.070 |
Why?
|
| Accidental Falls | 2 | 2020 | 10 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2007 | 16 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2006 | 7 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 13 | 0.060 |
Why?
|
| World Health Organization | 2 | 2016 | 3 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 20 | 0.060 |
Why?
|
| Research Design | 2 | 2017 | 41 | 0.060 |
Why?
|
| Alberta | 3 | 2010 | 3 | 0.060 |
Why?
|
| Information Dissemination | 2 | 2016 | 16 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2005 | 8 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2005 | 10 | 0.060 |
Why?
|
| Dietary Carbohydrates | 1 | 2005 | 8 | 0.060 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2005 | 1 | 0.060 |
Why?
|
| Firefly Luciferin | 1 | 2005 | 1 | 0.060 |
Why?
|
| Dietary Sucrose | 1 | 2005 | 6 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 40 | 0.060 |
Why?
|
| Luciferases | 1 | 2005 | 10 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 2 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2005 | 33 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 4 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2005 | 5 | 0.060 |
Why?
|
| Polyethylenes | 1 | 2004 | 1 | 0.060 |
Why?
|
| Epoxy Compounds | 1 | 2004 | 4 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2004 | 1 | 0.060 |
Why?
|
| Mice | 1 | 2007 | 746 | 0.050 |
Why?
|
| Piperidines | 1 | 2024 | 7 | 0.050 |
Why?
|
| Regenerative Medicine | 1 | 2024 | 2 | 0.050 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 16 | 0.050 |
Why?
|
| Tissue Engineering | 1 | 2024 | 4 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2024 | 13 | 0.050 |
Why?
|
| Vegetarians | 1 | 2023 | 1 | 0.050 |
Why?
|
| Causality | 1 | 2004 | 8 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2004 | 12 | 0.050 |
Why?
|
| Acute-Phase Reaction | 1 | 2003 | 1 | 0.050 |
Why?
|
| Diet, Gluten-Free | 1 | 2023 | 1 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 50 | 0.050 |
Why?
|
| Rats | 1 | 2005 | 571 | 0.050 |
Why?
|
| Iron-Dextran Complex | 1 | 2003 | 1 | 0.050 |
Why?
|
| Thyroxine | 1 | 2024 | 33 | 0.050 |
Why?
|
| Avitaminosis | 1 | 2003 | 1 | 0.050 |
Why?
|
| Biological Specimen Banks | 1 | 2023 | 2 | 0.050 |
Why?
|
| Reference Standards | 1 | 2022 | 2 | 0.050 |
Why?
|
| Serum Globulins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2022 | 27 | 0.050 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2002 | 2 | 0.050 |
Why?
|
| Basement Membrane | 1 | 2002 | 11 | 0.050 |
Why?
|
| Social Networking | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hematuria | 1 | 2002 | 4 | 0.050 |
Why?
|
| Puerto Rico | 1 | 2022 | 6 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 2 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2022 | 82 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 9 | 0.050 |
Why?
|
| Shiga Toxin | 1 | 2022 | 1 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2022 | 2 | 0.050 |
Why?
|
| Acute Disease | 2 | 2016 | 91 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 7 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 5 | 0.050 |
Why?
|
| Carotenoids | 1 | 2002 | 1 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 3 | 0.050 |
Why?
|
| San Francisco | 1 | 2001 | 13 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 53 | 0.040 |
Why?
|
| Acute-Phase Proteins | 1 | 2001 | 1 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2021 | 5 | 0.040 |
Why?
|
| Atenolol | 1 | 2020 | 1 | 0.040 |
Why?
|
| Metoprolol | 1 | 2020 | 1 | 0.040 |
Why?
|
| Nadolol | 1 | 2020 | 1 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2020 | 1 | 0.040 |
Why?
|
| Propranolol | 1 | 2020 | 5 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2021 | 11 | 0.040 |
Why?
|
| Labetalol | 1 | 2020 | 2 | 0.040 |
Why?
|
| Administrative Personnel | 1 | 2020 | 3 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 2020 | 4 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 9 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2020 | 2 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 6 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 17 | 0.040 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 5 | 0.040 |
Why?
|
| Hospitals | 1 | 2020 | 17 | 0.040 |
Why?
|
| Education, Medical | 1 | 2020 | 20 | 0.040 |
Why?
|
| Physicians | 1 | 2020 | 49 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 10 | 0.040 |
Why?
|
| Rosuvastatin Calcium | 1 | 2019 | 2 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 17 | 0.040 |
Why?
|
| Disaster Planning | 1 | 2019 | 3 | 0.040 |
Why?
|
| New York City | 1 | 2019 | 14 | 0.040 |
Why?
|
| Education | 1 | 2018 | 11 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2018 | 9 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 64 | 0.040 |
Why?
|
| Adiposity | 1 | 2018 | 20 | 0.040 |
Why?
|
| Research Report | 1 | 2018 | 1 | 0.030 |
Why?
|
| Arthrography | 1 | 1997 | 1 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 1997 | 1 | 0.030 |
Why?
|
| Whole Body Imaging | 1 | 2017 | 1 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 6 | 0.030 |
Why?
|
| Iran | 1 | 2017 | 68 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2016 | 8 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 16 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2016 | 34 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2016 | 5 | 0.030 |
Why?
|
| Cooking | 1 | 2016 | 1 | 0.030 |
Why?
|
| United Nations | 1 | 2016 | 1 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2016 | 9 | 0.030 |
Why?
|
| Biological Availability | 1 | 2016 | 8 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2016 | 23 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 12 | 0.030 |
Why?
|
| Bone Marrow | 1 | 1995 | 4 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 231 | 0.030 |
Why?
|
| Biological Transport | 1 | 2015 | 22 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 24 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 2015 | 6 | 0.030 |
Why?
|
| Oropharynx | 1 | 2015 | 2 | 0.030 |
Why?
|
| Skin Diseases, Infectious | 1 | 2015 | 2 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2015 | 3 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 16 | 0.030 |
Why?
|
| Antidiuretic Agents | 1 | 2014 | 1 | 0.030 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2014 | 9 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2014 | 44 | 0.030 |
Why?
|
| Phospholipids | 1 | 2014 | 6 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2014 | 9 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1994 | 3 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2013 | 7 | 0.030 |
Why?
|
| Dielectric Spectroscopy | 1 | 2013 | 1 | 0.030 |
Why?
|
| Plasma Volume | 1 | 2013 | 3 | 0.030 |
Why?
|
| Peptide Hormones | 1 | 2013 | 5 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 9 | 0.020 |
Why?
|
| Adipokines | 1 | 2013 | 3 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 6 | 0.020 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2012 | 4 | 0.020 |
Why?
|
| Hungary | 1 | 2011 | 1 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 2011 | 8 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 1 | 0.020 |
Why?
|
| Endotoxemia | 1 | 2011 | 2 | 0.020 |
Why?
|
| Blood Circulation | 1 | 2011 | 3 | 0.020 |
Why?
|
| Glycation End Products, Advanced | 1 | 2011 | 7 | 0.020 |
Why?
|
| Radiation Monitoring | 1 | 2010 | 3 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2010 | 10 | 0.020 |
Why?
|
| Phenylalanine | 1 | 2010 | 3 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 1 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2010 | 3 | 0.020 |
Why?
|
| Bias | 1 | 2010 | 5 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2010 | 23 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 110 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 71 | 0.020 |
Why?
|
| Apoptosis | 1 | 2010 | 179 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 56 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2007 | 15 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 2 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2004 | 27 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2002 | 3 | 0.010 |
Why?
|
| Collagen Type IV | 1 | 2002 | 4 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 97 | 0.010 |
Why?
|